Sotera Health Company

NasdaqGS:SHC Voorraadrapport

Marktkapitalisatie: US$4.5b

Sotera Health Beheer

Beheer criteriumcontroles 3/4

De CEO Sotera Health is Michael Petras, benoemd in Jun2016, heeft een ambtstermijn van 8.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.70M, bestaande uit 10.8% salaris en 89.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.91% van de aandelen van het bedrijf, ter waarde $ 85.47M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 4 jaar.

Belangrijke informatie

Michael Petras

Algemeen directeur

US$9.7m

Totale compensatie

Percentage CEO-salaris10.8%
Dienstverband CEO8.4yrs
Eigendom CEO1.9%
Management gemiddelde ambtstermijn4.1yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sep 02
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Jun 25
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 30
Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Mar 21
The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01
Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Feb 08

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Feb 06
Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Dec 28
Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Dec 11
Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sep 10
An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jun 05
Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Feb 13
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Nov 24
Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit

Sep 19

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sep 08
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Analyse CEO-vergoeding

Hoe is Michael Petras's beloning veranderd ten opzichte van Sotera Health's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$70m

Jun 30 2024n/an/a

US$40m

Mar 31 2024n/an/a

US$55m

Dec 31 2023US$10mUS$1m

US$51m

Sep 30 2023n/an/a

-US$306m

Jun 30 2023n/an/a

-US$268m

Mar 31 2023n/an/a

-US$261m

Dec 31 2022US$17mUS$1m

-US$234m

Sep 30 2022n/an/a

US$121m

Jun 30 2022n/an/a

US$123m

Mar 31 2022n/an/a

US$135m

Dec 31 2021US$2mUS$1m

US$115m

Sep 30 2021n/an/a

US$36m

Jun 30 2021n/an/a

US$9m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$17mUS$728k

-US$39m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$2mUS$700k

-US$21m

Compensatie versus markt: De totale vergoeding ($USD 9.70M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.66M ).

Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Michael Petras (55 yo)

8.4yrs

Tenure

US$9,701,005

Compensatie

Mr. Michael B. Petras Jr., serves as Chief Executive Officer at Sotera Health Company since June 20, 2016. He has been Chairman of the Board at Sotera Health Company since October 2020. He also served as t...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Michael Petras
Chairman & CEO8.4yrsUS$9.70m1.91%
$ 85.5m
Jonathan Lyons
Senior VP & CFO1.4yrsUS$2.18m0.039%
$ 1.7m
Alexander Dimitrief
Senior VP2yrsUS$862.18k0.083%
$ 3.7m
Michael Rutz
President of Sterigenics4.1yrsUS$2.03m0.17%
$ 7.5m
Robert Hauzie
Chief Information Officer5.8yrsgeen gegevensgeen gegevens
Kristin Gibbs
Chief Marketing Officer8yrsgeen gegevensgeen gegevens
William Lehmann
Senior Vice President of Strategy & Corporate Development2.8yrsgeen gegevensgeen gegevens
Sally Turner
Chief Human Resources Officer5.8yrsgeen gegevensgeen gegevens
Danielle Menture
Senior Vice President of Global Environmentalless than a yeargeen gegevensgeen gegevens
Joseph Shrawder
President of Nelson Labs4.1yrsgeen gegevensgeen gegevens
Riaz Bandali
President of Nordion2.8yrsgeen gegevensgeen gegevens
Jason Peterson
VP & Treasurerno datageen gegevensgeen gegevens

4.1yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SHC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Michael Petras
Chairman & CEO8.4yrsUS$9.70m1.91%
$ 85.5m
James Neary
Independent Director4.1yrsUS$320.00k0.015%
$ 656.5k
Constantine Mihas
Independent Director4.1yrsUS$305.00k0.015%
$ 656.5k
Sean Cunningham
Independent Director4.1yrsUS$302.50k0.015%
$ 656.5k
Vincent Petrella
Independent Director4yrsUS$325.00k0.015%
$ 656.5k
Christopher Simon
Independent Directorless than a yeargeen gegevensgeen gegevens
Ann Klee
Independent Director4.1yrsUS$322.50k0.031%
$ 1.4m
Robert Knauss
Independent Director2.1yrsUS$300.00k0.0056%
$ 248.4k
Ruoxi Chen
Independent Director4yrsUS$302.50k0.015%
$ 656.5k
David Wheadon
Independent Director3.5yrsUS$310.00k0.013%
$ 563.8k
Karen Flynn
Independent Directorless than a yearUS$9.99kgeen gegevens

4.0yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SHC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).